Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells.

Journal: Cell Stem Cell

Published: 2020-04-17

DOI: 10.1016/j.stem.2020.03.016

Affiliations: 21

Authors: 17

Go to article
Institutions Share
Department of Medical Oncology, DFCI, United States of America (USA) 0.12
Harvard Stem Cell Institute (HSCI), United States of America (USA) 0.09
Tufts Department of Immunology, United States of America (USA) 0.06
Department of Biomedical Engineering (BME), JHU, United States of America (USA) 0.06
Institute for Cell Engineering (ICE), JHU, United States of America (USA) 0.06
Department of Molecular, Cell and Cancer Biology (MCCB), UMass Medical School, United States of America (USA) 0.06
Li Weibo Institute for Rare Diseases Research, UMass Medical School, United States of America (USA) 0.06
Division of Hematology, UW, United States of America (USA) 0.06
Harvard Department of Pediatrics, United States of America (USA) 0.06
Department of Pediatric Oncology, DFCI, United States of America (USA) 0.06
Division of Hematology/Oncology, BCH, United States of America (USA) 0.06
Stem Cell Program, BCH, United States of America (USA) 0.03
The Manton Center for Orphan Disease Research, BCH, United States of America (USA) 0.03
HMS Initiative for RNA Medicine (HIRM), BIDMC, United States of America (USA) 0.03
Brigham Regenerative Medicine Center (BRMC), BWH, United States of America (USA) 0.03
Division of Cardiovascular Medicine, BWH, United States of America (USA) 0.03
Harvard Department of Medicine, United States of America (USA) 0.03
Broad Institute of MIT and Harvard, United States of America (USA) 0.02
Fred Hutchinson Cancer Research Center (FHCRC), United States of America (USA) 0.02
Seattle Children's Hospital, United States of America (USA) 0.02
Department of Pediatrics, UW, United States of America (USA) 0.02

Return

Except where otherwise noted © 2020 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER